亚洲欧美精品在线-亚洲欧美精品中文字幕在线观看-亚洲欧美精品综合在线观看-亚洲欧美精选-亚洲欧美久久-亚洲欧美久久精品

Hello! Welcome to the official website of Betta Pharmaceuticals!
Service Hotline:+86-571-86130357     Add to Favorites | Online Feedback 中文

Betta Pharmaceuticals Co., Ltd. was established in 2003 and is headquartered in Hangzhou, Zhejiang. It is a national high-tech enterprise established by an experienced team with talented returnees, focusing on research and development (R&D) of innovative drugs, with entire close loops of R&D, manufacturing, and sales. On Nov. 7th,2016, Betta Pharmaceuticals was successfully listed on the Shenzhen Stock Exchange with the stock code: 300558.SZ.

The company has more than 1,700 employees, and has established a senior executive team for innovative drug discovery and commercialization, including dozens of returnees (Ph.D.). The company has set up R&D centers in Beijing, Hangzhou. The company independently developed China's first small molecule anti-cancer drug for EGFR-targeted therapy——Icotinib hydrochloride (trade name: Conmana?), which was approved by the National Medical Products Administration (NMPA) in June 2011. Conmana? has won the Gold Prize of China Patent Award twice as well as the China Industrial Award. It has also been awarded for the National Prize for Progress in Science and Technology, as the first such award granted to a China's chemical pharmaceutical industry and to a Zhejiang enterprise.

In November 2020, Ensartinib hydrochloride capsule (trade name: Ensacove?), which is an innovative drug with independent intellectual property rights, that was jointly developed by Betta and its holding subsidiary Xcovery, was approved by NMPA. It became the first Category 1.1 new drug manufactured domestically in China for the treatment of advanced non-small cell lung cancer (NSCLC) with ALK mutations, which has filled the gap in the same class of drugs in China.

In November 2021, the Bevacizumab injection jointly developed by Betta and Beijing Mabworks Biotechnology Co., Ltd. was officially approved for marketing, with approved indication is of metastatic colorectal cancer and advanced, metastatic, or recurrent NSCLC. Bevacizumab became the company's first approved biological macromolecular drug, which is also the third marketed drug and the first bevacizumab biosimilar in Zhejiang.

In May 2023, Betta’s fourth marketed drug Befotertinib (trade name: Surmana?) was approved. The third-generation EGFR-TKI is indicated for locally advanced or metastatic NSCLC with T790M mutation due to first-generation EGFR-TKI resistance. The launch of the drug demonstrates Betta’s remarkable R&D capability. The Lancet Respiratory Medicine commented that Befotertinib (Surmana?) as a new candidate in the field of EGFR-mutant advanced NSCLC that can be considered as an alternative strategy for patients in China.

In June 2023, the Category 1 innovative drug Vorolanib was approved by the NMPA used in combination with Everolimus, indicated for the treatment of patients with advanced renal cell carcinoma who progressed after TKI treatment. The drug demonstrates a breakthrough in the field of domestic innovative drugs for renal cell carcinoma. 

The company gives full play to its role as the main body of scientific and technological innovation, and continues to increase investment in research and development of new drugs for major diseases that seriously affect human health.Betta’s R&D expenditure increased continuously in the past three years, and has an average of over 40% of the company’s total expenditure. The company has a robust in-house portfolio, 2 programs have been granted NDA approval, and 23 have entered various clinical stages. Ensartinib is currently under FDA review for US market approval, and has the potential to become the first globally launched small-molecule anti-cancer innovative drug led by a Chinese company.

Actively responding the call from the industry, the company also set up a healthcare innovation incubator platform——Betta Dreamworks, to help more scientists achieve their dreams of innovation and entrepreneurship.





主站蜘蛛池模板: av中文字幕在线播放 | 日本三级韩国三级在线观看a级 | 国产人妻人伦精品久久无码 | 一本久道久综合久久鬼色 | 免费看一级高潮毛片高清a 免费看一区二区三区 | 成人网站免费大全日韩国产 | 国产精品自在线拍国产手青青机版 | 国产成人精品高清在线观看99 | 日本三日本三级香港三级 | 久久h视频 | 国产黄A三级三级三级AV在线看 | 一区二区日本精品理论片 | 欧美一区综合 | 好湿好紧快点再深一点动图 | 波多野结衣一区二区三区四区视频 | 国产成人亚洲毛片 | 欧洲乱码卡1卡2在线 | 国产成人av乱码免费观看 | 国产三级精品在线免费观看 | 久久久精品久久波多野结衣av | 精品久久免费观看 | 精品久久a人妻 | 丝袜自慰一区二区三区 | 麻豆小偷闯空门巧遇空 | 精品亚洲?ⅴ无码午夜在线 精品亚洲a∨无码一区二区三区 | 久久精品国产日韩不卡 | 国产精品久片在线观看 | 免费人成在线观看网站品爱网 | 久久久久国产精品免费免费播放付 | 日韩伦理在线免费观看 | 日韩18视频在线观看 | 久久这里只有是精品23 | 欧美日本一道高清二区三区 | 91麻豆精品一二三区在线国语 | 日本欧美国产中文字幕 | 久久人妻一区二区三区欧美 | 久久精品国产亚洲欧美 | 91欧美精品 | 91无码精品视频 | 高清不卡v免费费 | av天堂高清国产资源网 |